TN-001 eyedrops for progressive keratoconus
Part of Eyes & vision clinical trials.
This trial tests a new eyedrop (TN-001) for people with keratoconus that is getting worse. The drops are applied twice a day to try to stop the cornea from thinning and bulging further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 40 years old.
- You have keratoconus that is getting worse (progressive).
- Your cornea is at least as thick as a credit card (400 microns).
- You are not currently using contact lenses or other eye drops for dry eyes.
- You have not had any previous eye surgeries or procedures like corneal cross-linking.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an eye drop called GLK-221 for people with keratoconus, a condition where the clear front of the eye bulges. The goal is to see if the drops can safely help improve the condition compared to a placebo (an inactive solution).
This study follows people with or at risk for keratoonus, a condition where the cornea thins and bulges. It aims to improve early detection and understand how the disease progresses.
This trial compares two ways to manage inflammation after corneal crosslinking for keratoconus: a tiny steroid insert placed in the tear duct versus standard steroid eye drops. It aims to see which option is easier and works just as well.
This study tests whether treating donor corneal tissue with a special light and vitamin drops (called cross-linking) before a transplant helps improve outcomes for people with keratoconus. If you need a corneal transplant, this could strengthen the donor tissue and potentially reduce the need for future procedures.
This study tests a procedure called corneal crosslinking to slow or stop the progression of keratoconus or corneal ectasia. It might help keep your cornea stable and prevent further vision loss.
This trial uses donated corneal tissue that was treated with a special light and riboflavin (collagen cross-linking) to strengthen it before transplant. The goal is to improve vision in people with severe keratoconus, a condition where the cornea bulges into a cone shape and gets very thin.
Hear when a new Keratoconus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.